Technology area: Biotechnology & Pharmaceuticals
25 pending office actions • 12 clients • 24 examiners • 19 art units • 0 of 25 (0%) have an AI response strategy ready
This profile covers Biotechnology & Pharmaceuticals and shows 25 pending office actions. Its 538 career applications provide a recorded historical base for the current workload.
The resolved allowance rate is 68.95%, and the average is 3.61 office actions per allowance. The resolved record indicates allowance in a smaller share of matters than non-allowance, while allowances generally followed several office actions.
For practitioners, the figures support close attention to claim strategy, amendment choices, and response timing. The allowance rate frames the historical outcome challenge, and the action average indicates that matters reaching allowance may require sustained prosecution effort.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (8%) |
| §103 only | 5 (20%) |
| §112 only | 2 (8%) |
| Double-patenting only | 1 (4%) |
| Double-patenting + other | 1 (4%) |
| Multi-statute (no §101) | 14 (56%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STOICA, ELLY GERALD | 2 | 66.8% | +22.6% |
| BLUMEL, BENJAMIN P | 1 | 70.7% | +30.6% |
| BAUER, NICOLA MARIA | 1 | 58.7% | +52.1% |
| BOECKELMAN, JACOB A | 1 | 34.9% | +46.5% |
| MONTANARI, DAVID A | 1 | 64.8% | +49.0% |
| ABBAS, SYED JARAR | 1 | 25.0% | +0.0% |
| WANG, CHANG YU | 1 | 33.4% | +53.7% |
| YU, HONG | 1 | 31.1% | +5.7% |
| GOLDBERG, JEANINE ANNE | 1 | 45.4% | +40.5% |
| TCHERKASSKAYA, OLGA V | 1 | 55.5% | +46.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18066567 | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF ADENO-ASSOCIATED VIRUS | GONZALES, JOSEPHINE MARIA | 69d |
| 17909427 | Replication Competent Virus Assay | WANG, RUIXUE | 69d |
| 18940528 | Deamidation Depleted Adeno-Associated Virus Product | BLUMEL, BENJAMIN P | — |
| 18859396 | USE OF LAT1 INHIBITORS TO TREAT OBESITY | BAUER, NICOLA MARIA | — |
| 18833550 | METHOD FOR THE PRODUCTION OF A PLANT EXTRACT | BOECKELMAN, JACOB A | — |
| 18657524 | ENHANCED GENE DELIVERY METHODS | MONTANARI, DAVID A | — |
| 18707578 | IL33 PROTEINS AND METHODS OF USE THEREOF | ABBAS, SYED JARAR | — |
| 18627010 | BLOOD-BASED ASSAY FOR DETECTING TAUOPATHY OR AMYLOIDOGENIC DISEASE | WANG, CHANG YU | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18411193 | Pharmaceutical Composition and Method for Improving Biomechanical Integrity of the Pelvic Floor | TCHERKASSKAYA, OLGA V | 30d |
| 18940528 | Deamidation Depleted Adeno-Associated Virus Product | BLUMEL, BENJAMIN P | — |
| 18859396 | USE OF LAT1 INHIBITORS TO TREAT OBESITY | BAUER, NICOLA MARIA | — |
| 18833550 | METHOD FOR THE PRODUCTION OF A PLANT EXTRACT | BOECKELMAN, JACOB A | — |
| 18657524 | ENHANCED GENE DELIVERY METHODS | MONTANARI, DAVID A | — |
| 18627010 | BLOOD-BASED ASSAY FOR DETECTING TAUOPATHY OR AMYLOIDOGENIC DISEASE | WANG, CHANG YU | — |
| 18291113 | USE OF CIRCULATING CELL-FREE METHYLATED DNA TO DETECT TISSUE DAMAGE | GOLDBERG, JEANINE ANNE | — |
| 18575804 | Method of Administering Anti-HPA-1a Monoclonal Antibody | STOICA, ELLY GERALD | — |
| Art Unit | Apps |
|---|---|
| 1631 | 3 |
| 1632 | 2 |
| 1682 | 2 |
| 1647 | 2 |
| 1628 | 2 |
| 1671 | 1 |
| 1621 | 1 |
| 1655 | 1 |
| 1674 | 1 |
| 1675 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18940528 | Deamidation Depleted Adeno-Associated Virus Product | Oxford Biomedica (Us) LLC | BLUMEL, BENJAMIN P | 1671 | §102§103§112 | Non-Final OA | — | Pending | Nov 07, 2024 |
| 18859396 | USE OF LAT1 INHIBITORS TO TREAT OBESITY | Georgetown University | BAUER, NICOLA MARIA | 1621 | §102§103 | Non-Final OA | — | Pending | Oct 23, 2024 |
| 18833550 | METHOD FOR THE PRODUCTION OF A PLANT EXTRACT | Vertanical GmbH | BOECKELMAN, JACOB A | 1655 | §102§103§112 | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18657524 | ENHANCED GENE DELIVERY METHODS | Angiocrine Bioscience, Inc. | MONTANARI, DAVID A | 1632 | §103§112 | Non-Final OA | — | Pending | May 07, 2024 |
| 18707578 | IL33 PROTEINS AND METHODS OF USE THEREOF | Memorial Sloan Kettering Cancer Center | ABBAS, SYED JARAR | 1674 | §102§112 | Non-Final OA | — | Pending | May 04, 2024 |
| 18627010 | BLOOD-BASED ASSAY FOR DETECTING TAUOPATHY OR AMYLOIDOGENIC DISEASE | Janssen Pharmaceutica NV | WANG, CHANG YU | 1675 | §101§102§112DP | Non-Final OA | — | Pending | Apr 04, 2024 |
| 18622971 | Pharmaceutical Composition and Method for Treating or Preventing Candidiasis | Fempharma, LLC | YU, HONG | 1614 | §103 | Final Rejection | 22d | Pending | Mar 31, 2024 |
| 18291113 | USE OF CIRCULATING CELL-FREE METHYLATED DNA TO DETECT TISSUE DAMAGE | Georgetown University | GOLDBERG, JEANINE ANNE | 1682 | §101§102§103§112 | Non-Final OA | — | Pending | Jan 22, 2024 |
| 18411193 | Pharmaceutical Composition and Method for Improving Biomechanical Integrity of the Pelvic Floor | Fempharma, LLC | TCHERKASSKAYA, OLGA V | 1615 | §112 | Final Rejection | 30d | Pending | Jan 12, 2024 |
| 18575804 | Method of Administering Anti-HPA-1a Monoclonal Antibody | Rallybio Ipa, LLC | STOICA, ELLY GERALD | 1647 | §102§103§112 | Non-Final OA | — | Pending | Dec 29, 2023 |
| 18575805 | Administration of Anti-HPA-1a Antibodies | Rallybio Ipa, LLC | STOICA, ELLY GERALD | 1647 | §103DP | Non-Final OA | — | Pending | Dec 29, 2023 |
| 18570043 | Treatment of Inflammatory Conditions or Diseases | Queen Mary University Of London | FAUST, AMBER KATHLEEN | 1643 | §102§103§112 | Non-Final OA | — | Pending | Dec 13, 2023 |
| 17792557 | METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY | Memorial Sloan Kettering Cancer Center | LEE, CHIHYI NMN | 1628 | §103§112 | Non-Final OA | — | Pending | Jun 20, 2023 |
| 18138058 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Georgetown University | BARSKY, JARED | 1628 | §103 | Final Rejection | 89d overdue | Pending | Apr 22, 2023 |
| 18249248 | INDUCTION OF FERROPTOSIS FOR CANCER THERAPY | Memorial Sloan Kettering Cancer Center | HUDSON, AMY ROSE | 1636 | §102§103§112 | Non-Final OA | — | Pending | Apr 15, 2023 |
| 18041080 | CRYOPRESERVED ENDOTHELIAL CELL COMPOSITIONS | Angiocrine Bioscience, Inc. | ABBOTT, KODYE LEE | 1634 | §103§112 | Non-Final OA | — | Pending | Feb 09, 2023 |
| 17924980 | METHOD OF TREATMENT OF CANCER OR TUMOUR | USWM CT,LLC | POPA, ILEANA | 1633 | §102§103§112Other | Non-Final OA | — | Pending | Jan 23, 2023 |
| 18003124 | ENDOTHELIAL CELLS FOR MITIGATION OF CHEMOTHERAPY-INDUCED TOXICITY | Angiocrine Bioscience, Inc. | SCHUBERG, LAURA J | 1631 | §103Other | Final Rejection | 25d overdue | Pending | Dec 22, 2022 |
| 18011171 | Administration of CEBP-Beta Antagonist and Methods of Use | Sapience Therapeutics, Inc. | STEELE, AMBER D | 1658 | DP | Non-Final OA | — | Pending | Dec 17, 2022 |
| 18066567 | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF ADENO-ASSOCIATED VIRUS | Oxford Biomedica (Us) LLC | GONZALES, JOSEPHINE MARIA | 1631 | §102§103 | Non-Final OA | 69d | Pending | Dec 15, 2022 |
| 17921606 | METHODS FOR ISOLATING AND CULTURING TUMOR CELLS | Georgetown University | TRAN, KHOA NHAT | 1632 | §103§112 | Non-Final OA | — | Pending | Oct 26, 2022 |
| 17909427 | Replication Competent Virus Assay | Oxford Biomedica (Uk) Limited | WANG, RUIXUE | 1672 | §103§112 | Final Rejection | 69d | Pending | Sep 05, 2022 |
| 17629378 | Enhancing Production of Lentiviral Vectors | Oxford Biomedica (Uk) Limited | BATES, KEENAN ALEXANDER | 1631 | §112Other | Final Rejection | — | Pending | Jan 22, 2022 |
| 17293372 | METHOD, SOLUTION AND KIT FOR PREPARING A TISSUE SAMPLE FOR 3D IMAGING | The Francis Crick Institute Limited | REGLAS, GEORGIANA C | 1651 | §103 | Non-Final OA | — | Pending | May 12, 2021 |
| 17196631 | METHODS AND COMPOSITIONS FOR DETECTION OF HPV DNA AND DIAGNOSIS AND MONITORING OF HPV-ASSOCIATED CANCERS | Memorial Sloan Kettering Cancer Center | HANEY, AMANDA MARIE | 1682 | §103 | Non-Final OA | 7d | Pending | Mar 09, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial69.0% of resolved applications prosecuted by Grimes & Yvon LLP were allowed, across 538 applications in USPTO records.
3.61 office actions per allowed application on average.
25 pending office actions as of October 2026, for 12 clients, before 24 examiners in 19 art units.
